And We Have a $26.4 Billion Winning Trifecta!

THREE PREVIOUS WINNERS* Immunomedics (IMMU) $3 to $87 up 2,800%, a gain of $20.7 billion. Acquired...

Selling ARK (ARKK) & Buying AXS Short Innovation (SARK) ETF.

Going Short the Market. No Long Dissertation, No Rush. Market Risk Has Appeared, With Minimal Upside, So Time To Act.

Sanofi (SNY) to Acquire Provention Bio (PRVB) for $25 a Share. Gains 243%.

Up 416%, from Adding it to 2022 Watch List! Great way to wake up after a night of hard...
Internet Stock Review, Biotech Stock Review, Roland Rick Perry

Unicycive Therapeutics (UNCY) $2.73 Tacks on Another 30%. We’re now up 249%.

Quick way to Jinx Things... Stormin..Live Quote We're still not...

Meet Dennis Nguyen CEO of Start-Up Investor, the Society Pass (Symbol: SOPA)

See a Dazzling Presentation! Society Pass (SOPA) has quickly acquired 8 companies since going public in late 2021,...

New Player in the Electric Vehicle (EV) Market?

Principal Solar (PSWW) Highlights one of it's Portfolio Holdings, eTruck Transportation. Alternative Energy...

Freedom Holding (FRHC) Acquires LD Micro From SRAX, Inc

Purchase bringsĀ pre-eminent small-cap platform to the Freedom family Freedom U.S. Markets, LLC, a wholly-owned subsidiary of Freedom Holding Corp....
Unicycive

Unicycive (UNCY) Shoots and Scores, up 40% Today!

We're up 126% Since December, and That Ain't Bad. Note: This isn't the end, it's just the...

Booya. We’re up 143% With Ardelyx (ARDX) in Three Months – and That Ain’t...

Ardelyx Adds 16% to $3.82 as Wedbush Upgrades After Q4 Earnings. Ardelyx ( NASDAQ: ARDX ) gained 35%...

We Warned About VERU (VERU) $2.50, Down 89%.

Down 35% Today, and 89% from $24, and a $1.9 Billion Market Cap, Only 7 Months ago. The FDA...

Latest article

Institutional Analyst Newsletter. Citius (CTXR), GeoVax (GOVX.

DERBY WEEKEND - WE'RE HEADED TO TAMPA!HAT'S ON, DRINK'S UPADDING CITIUS PHARMA (CTXR) $0.66, TO WATCHLISTUPDATING GEOVAX LABS (GOVX) $1.43OUR $26...

Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.

Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!

Citius Pharmaceuticals (CTXR) Prospectus, Powerpoint & Fact Sheet.

CRANFORD, N.J., April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization...